Therefore, from a clinical perspective, the balance between IL-1 agonists, antagonists, and the amount of surface as well as soluble IL-1Rs affect the overall degree and severity of inflammation in several diseases, including IBD. This evidence concerns the gene IL1A and irritable bowel syndrome.